Chardan Capital Rates ProQR Therapeutics (PRQR) buy

Chardan Capital maintains its buy rating on PRQR with a $3 price target, a 91.69% upside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 9:01 AM EDT · Updated Jun 27, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Chardan Capital rated ProQR Therapeutics N.V. ($PRQR) "buy" with a $3 price target on June 26, 2026.

Since the rating, $PRQR is up 12.4% after 1 week, up 13.1% after 1 month and down 14.4% to date (from the $1.53 close on Jun 26, 2026).

PRQR ProQR Therapeutics N.V.

$1.31 -34.17% year to date

Daily close · Oct 16, 2026

Key Points

Chardan Capital reiterated its buy rating for PRQR, setting a $3 price target on June 26, 2026.
Chardan Capital's $3 price target implies 91.69% upside from ProQR Therapeutics N.V.'s ($PRQR) current $1.56 share price.
PRQR shares traded at $1.56 on Friday, with notable institutional activity from peers such as Privium Fund Management and Aberdeen Group.
Insider Hinsch Gylvin Lykke bought 14,495 shares on June 2, 2026, reflecting ongoing interest in the company.

Get $PRQR trade alerts by text

We text you when insiders, Congress or big funds trade $PRQR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ProQR Therapeutics N.V. alert may contain errors. Disclosures

Chardan Capital has reiterated its buy rating for PRQR, setting a price target of $3. This announcement was made on June 26, 2026, by analyst Keay Nakae. On the same day, PRQR shares were trading at $1.56.

Other Institutional Activity in PRQR

Several institutional investors have been active in PRQR. Privium Fund Management B.V. increased its holdings by 109,387 shares, bringing its total to 5,467,149 shares valued at approximately $8.86 million, marking a 2.0% increase. Aberdeen Group PLC also grew its stake by 366,289 shares, totaling 3,316,965 shares worth about $5.37 million, reflecting a 12.4% increase. Conversely, SIO Capital Management, LLC reduced its holdings by 209,466 shares, ending with 1,954,715 shares valued at roughly $3.17 million, a decrease of 9.7%.

ProQR Therapeutics N.V. Stock Down 14.5%

Shares of PRQR traded at $1.56 on Friday. The stock has seen varied activity among institutional investors, with some increasing their positions and others trimming their stakes. This mixed activity highlights the diverse perspectives on the company's potential.

12-month forecast

$PRQR price target

ProQR Therapeutics N.V. daily closes and this analyst's $3 target. Not advice.

Insider Buying and Selling at ProQR Therapeutics N.V.

On June 2, 2026, insider Hinsch Gylvin Lykke purchased 14,495 shares of PRQR. This transaction was not pre-planned under a Rule 10b5-1 plan, indicating a direct investment decision.

Analysts Set New Price Targets

On June 26, 2026, Chardan Capital maintained its buy rating for PRQR with a price target of $3. This follows a previous target of $4 set on April 9, 2026. The consensus among analysts remains positive, with a general buy recommendation.

Bottom Line

Chardan Capital's reiterated buy rating for PRQR with a $3 target reflects continued confidence in the company's prospects. Institutional and insider activities suggest varying levels of interest and investment strategies. As always, these analyst ratings and institutional moves are backward-looking and should be considered as part of a broader investment strategy.